LMLiala Moschetti

Liala Moschetti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liala Moschetti has a total of 186 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lupus Remission: How Do Patient and Physician Perceptions Align?

    by Chiara Orlandi, Micaela Fredi, Cesare Tomasi, Martina Salvi, Cecilia Nalli, Chiara Bazzani, Liala Moschetti, Ilaria Cavazzana, Franco Franceschini

    Objective: Clinical remission is a major therapeutic goal in systemic lupus erythematosus (SLE) because of its association with improved long-term outcomes. However, its relationship with patient-reported burden, quality of life, and disease perception remains incompletely understood. This study aimed to evaluate patient-reported outcomes (PROs) in patients with SLE in clinical remission, identify factors associated with impaired health-related quality of life (HRQoL), and assess physician–patient discordance in disease activity perception. Methods: A total of 106 adult patients with SLE in clinical remission according to the definition proposed by Zen et al. were enrolled at a single rheumatology center. Patients were classified into complete remission, clinical remission off corticosteroids, or clinical remission on corticosteroids. Demographic, clinical, and treatment-related data were collected, including organ damage (SLICC-SDI) and disease activity (SLEDAI-2K). Patients completed PRO measures including SF-36, Global Health (GH), pain VAS, STAI-Y1 and STAI-Y2, Zung Depression Scale, Insomnia Severity Index, and HAQ. Disease activity was assessed by both the patient (PGA) and the physician (PhGA); a PGA–PhGA difference >25 mm was considered clinically relevant discordance. Results: Among patients in clinical remission, mild anxiety was observed in 17.1% according to STAI-Y1 and in 27.9% according to STAI-Y2, mild-to-moderate depressive symptoms in 47.1%, and mild insomnia in 25.5%. Of the 106 patients, 24 (22.6%) were in complete remission, 27 (25.5%) in clinical remission off corticosteroids, and 55 (51.9%) in clinical remission on corticosteroids. Patients in clinical remission on corticosteroids showed worse patient-reported outcomes than those in complete remission or clinical remission off corticosteroids. In multivariable analyses, poorer physical HRQoL was independently associated with functional disability, pain intensity, and depressive symptoms, whereas poorer mental HRQoL was independently associated with trait and state anxiety. Clinically relevant physician–patient discordance was observed in 22.6% of the cohort and was almost exclusively driven by higher patient than physician scores. Pain intensity emerged as the most robust independent correlate of discordance. Conclusions: A substantial patient-reported burden may persist in patients with SLE despite clinical remission. Pain, psychological distress, insomnia, and functional disability contribute to impaired HRQoL, while physician–patient discordance appears to reflect a broader mismatch between inflammatory disease control and the patient’s lived experience of illness. These findings support a more comprehensive and patient-centered approach to remission assessment in SLE.

  • Open Access

    Monoclonal Antibodies in Pregnancy of Patients with Systemic Lupus Erythematosus: Friend or Foe? A Case Report of a Patient with Multiple Pregnancies

    by Chiara Orlandi, Angela Tincani, Micaela Fredi, Laura Andreoli, Francesca Crisafulli, Liala Moschetti, Cecilia Nalli, Maria Grazia Lazzaroni, Marco Taglietti, Matteo Filippini, et al.

    Systemic lupus erythematosus (SLE) is an autoimmune disease that predominantly affects women of childbearing age, and active disease during pregnancy is associated with increased maternal and fetal morbidity. Belimumab is an effective biologic therapy for active SLE; however, its use during pregnancy has long been limited by the scarcity of safety data. Recent evidence and updated international recommendations suggest that belimumab may be considered in selected cases when required to maintain maternal disease control. We report the case of a woman with SLE who experienced three consecutive pregnancies with live births between 2019 and 2024 while receiving belimumab, allowing an intra-individual comparison of different exposure strategies. During the first pregnancy, belimumab was discontinued at conception and was followed by a disease flare in late pregnancy and postpartum. In the second and third pregnancies, belimumab was continued until gestational week 20 following shared decision-making with the patient; nevertheless, disease flares occurred during the third trimester of both pregnancies. All pregnancies resulted in live births at term, with no congenital anomalies, placental insufficiency, or fetal growth restriction. One neonate from the third pregnancy developed early-onset neonatal sepsis and meningitis, which resolved completely after antibiotic treatment. All children are currently growing and developing normally. This case supports a risk-adapted approach to belimumab use during pregnancy. In selected women with SLE at high risk of disease reactivation, continuation of belimumab until mid-gestation may contribute to improved maternal disease control without evident adverse fetal outcomes.

  • Open Access

    The clinical phenotype of anti-Th/To+ patients in systemic sclerosis: a case-control study within the European Scleroderma Trials and Research cohort

    by Liala Moschetti, Silvia Rovaris, Francesco Bonomi, Helena Codes-Mendez, María Martín-López, Fabio Cacciapaglia, Antonio Tonutti, Francesco Del Galdo, Corrado Campochiaro, Marie Elise Truchetet, et al.

    Background: Systemic sclerosis (SSc) is a heterogeneous autoimmune disease, where autoantibody profiling plays a central role in defining disease subsets and guiding personalized management. Objectives: To investigate the clinical phenotype and long-term outcomes of anti-Th/To positive SSc patients in an international cohort, focusing on interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), malignancy association, organ damage accrual, and mortality within a precision medicine framework. Design: Multicenter case-control study. Methods: Data prospectively collected from 28 European Scleroderma Trial and Research centers were analyzed (CP144). For each anti-Th/To+ case, two anti-Th/To− controls were matched by sex, age at onset, and disease duration to enable detailed phenotypic comparisons. Results: A total of 102 anti-Th/To+ patients were compared to 204 anti-Th/To− matched controls. Anti-Th/To+ patients had a higher prevalence of concomitant anti-Ro52+, lower frequency of diffuse cutaneous involvement, digital ulcers, pitting scars, and telangiectasias. ILD on high-resolution computed tomography and ILD functional progression events were less frequent in anti-Th/To+ patients, and anti-Th/To positivity was not independently associated with ILD in multivariable analysis. Instead, ILD presence was significantly associated with anti-Topoisomerase-1 (anti-Topo1) and anti-Ro52 positivity, and lack of anticentromere antibodies. Similarly, myocarditis was less frequently observed in anti-Th/To+ cases, although myositis had a higher rate than in anti-centromere+ or other lcSSc patients. Other SSc manifestations, including PAH, and malignancies synchronous to SSc onset had similar frequencies between cases and controls. Anti-Th/To+ patients accrued mild organ damage during the disease course, with lower damage index scores than anti-Topo1+ matched controls. No SSc-related deaths occurred in anti-Th/To+ patients, who had survival curves slightly better, although not significantly different, than matched controls. Conclusion: Anti-Th/To+ SSc patients are characterized by low prevalence of major organ involvement, including ILD, when compared to matched controls, mild organ damage, and good survival. These results reinforce the ongoing use of autoantibody profiling—including rarer antibodies—in precision medicine for SSc.

  • Open Access

    Primary antiphospholipid syndrome and the kidney: biopsy-proven insights from two referral Italian centres

    by Liala Moschetti, Savino Sciascia, Micaela Fredi, Mattia Zappa, Massimo Radin, Ilaria Cavazzana, Stefania Affatato, Cecilia Nalli, Laura Andreoli, Federica Mescia, et al.

    Objectives: To investigate the prevalence, clinical features, histological spectrum and outcomes of intra-renal involvement in patients with primary APS (PAPS), with particular attention to both aPL nephropathy (aPL-N) and non-aPL-N renal lesions. Methods: This multicentric retrospective case–control study included 258 PAPS patients followed between 1984 and 2023 at two Italian referral centres. Patients with a biopsy-proven intra-renal involvement (n = 17) were compared with those without renal manifestations. Histologic classification followed the updated aPL-N criteria. Clinical, laboratory, therapeutic features, and 12-month renal responses were assessed. Results: Seventeen of 258 (7%) patients underwent renal biopsy. Two out of 17 (12%) presented with acute kidney injury, 5/17 (29%) with nephrotic syndrome and 5/17 (29%) had isolated urinary abnormalities; the remaining 5 patients presented with different combination of signs/symptoms. Six (2.3%) were diagnosed with aPL-N, while 11 (4.2%) exhibited alternative glomerular lesions (e.g. membranous nephropathy, focal segmental glomerulosclerosis). Compared with controls, patients with intra-renal involvement had higher frequencies of CAPS (18% vs 0.4%, P = 0.001), thrombocytopenia (35% vs 10%, P = 0.006), epilepsy (24% vs 5%, P = 0.018) and LA positivity (100% vs 62%, P = 0.002). At 12 months, partial renal response was observed in most cases, with a worse prognosis in those with aPL-N despite anti-thrombotic treatment. All non-aPL-N patients had aPL-related events, including thrombotic, obstetric and non-thrombotic manifestations, with non-aPL-N renal disease preceding these events in 45%. Conclusion: Intra-renal involvement in PAPS is rare but heterogeneous, encompassing both vascular and glomerular pathologies. These findings support the need for heightened renal surveillance in PAPS, even in the absence of classic thrombotic manifestations, and highlight the importance of histologic assessment to guide tailored therapy. From a nephrologist’s perspective, routine screening for aPL in glomerular disease assessment may be relevant, particularly by providing prognostic value for subsequent aPL-related events.


  • Open Access

    The use of tumor necrosis factor inhibitors during high-risk pregnancies in antiphospholipid syndrome: a clinical report of a patient with concomitant Takayasu arteritis and case-based review

    by Liala Moschetti, Francesca Crisafulli, Francesca Regola, Rossana Orabona, Sofia Pitsigavdaki, Franco Franceschini, Laura Andreoli, Sonia Zatti, Angela Tincani, Ebru Yılmaz, et al.

    In the field of obstetric antiphospholipid syndrome (APS), studies in mouse models and case reports support the potential benefit of tumor necrosis factor-α inhibitors (TNF-α-i ) in preventing pregnancy loss associated with APS. We present the case of a 36-year-old woman with a diagnosis of Takayasu arteritis who suffered from antiphospholipid antibody (aPL)-related thrombotic microangiopathy/probable catastrophic APS during her first pregnancy and who had a subsequent successful pregnancy while on treatment with certolizumab pegol (CZP), heparin, and low-dose aspirin. The report is followed by the literature review of published cases of APS or aPL-positive pregnancies treated with CZP or other TNF-α-i . A total of 20 pregnancies, including the one here presented, were reported in high-risk APS patients exposed to TNF-α-i , showing a favorable outcome in most pregnancies (80% live births, 69% absence of adverse pregnancy outcomes). Despite the limited available evidence, TNF-α-i could represent a promising option for high-risk patients in obstetric APS.

  • The impact of systemic sclerosis on women’s health evaluated with an ad hoc-developed patient-reported questionnaire

    by Maria-Grazia Lazzaroni, Liala Moschetti, Eleonora Pedretti, Laura Andreoli, Francesca Ramazzotto, Sonia Zatti, Ilaria Galetti, Paolo Airò, Angela Tincani, Franco Franceschini

    Objective: The impact of disease on women’s health-related quality of life has become increasingly important in patients with rheumatic diseases (RDs). Systemic sclerosis (SSc) mostly affects women with a broad spectrum of clinical presentations and severity, and a variable impact on daily living. The objective of the present study was to specifically address “women’s health” in systemic sclerosis patients through a dedicated questionnaire. Methods: An anonymous self-reported questionnaire (only in Italian) was developed in collaboration with obstetricians and gynecologists and subsequently revised and approved by five patient representatives. The questionnaire was administered to SSc patients during scheduled visits in an outpatient Rheumatology SSc Clinic. Results: Between April 2021 and March 2023, 168 patients accepted to participate; among them, 44.1% had received their SSc diagnosis during reproductive age (<45 years). The questionnaire was composed of 44 questions and included 5 sections encompassing different topics. A high rate of adherence to female cancer screening programs was recorded (86.9% for cervix and 93.6% for breast cancer), while a non-regular gynecological follow-up was observed in 36.4%, mostly in patients with more severe disease phenotype. Only 42.3% accepted to compile the Female Sexual Function Index (FSFI), which indicated a sexual dysfunction (score ⩽ 26.55) in 66.2% of patients. A worse sexual function was shown to be associated with different disease manifestations, including digital ulcers. More than 90% of patients who expressed a desire for pregnancy after diagnosis received medical pre-conception counseling and were satisfied with the information provided. In contrast, discussion about contraception occurred in 37.8% of patients who had been diagnosed during fertile age. Family planning still represents an unmet need, as 43.6% of patients did not achieve their desired family size, mainly due to concerns about their capacity to care for their children. Conclusion: The newly developed questionnaire provides a unique opportunity to comprehensively assess the experience of women with SSc. Disease burden was shown to negatively impact sexual function and adherence to regular gynecological visits. Furthermore, receiving a diagnosis during reproductive age may increase the likelihood of a reduced family size. Clinicians who take care of women with SSc should implement these domains into routine management, thus improving the health literacy of their patients.


  • Frailty assessment in patients with systemic sclerosis

    by Claudia Barison, Elda Piovani, Liala Moschetti, Eleonora Pedretti, Maria Grazia Lazzaroni, Franco Franceschini, Paolo Airò

    Full Papers; Authors: C. Barison, E. Piovani, L. Moschetti, E. Pedretti, M.G. Lazzaroni, F. Franceschini, P. Airò


  • Anti-Th/To antibodies in systemic sclerosis: analysis of long-term follow-up of pulmonary involvement, organ damage accrual and mortality in an Italian cohort with a case-control study

    by Liala Moschetti, Maria Grazia Lazzaroni, Ilaria Cavazzana, Franco Franceschini, Paolo Airò

    Full Papers; Authors: L. Moschetti, M.G. Lazzaroni, I. Cavazzana, F. Franceschini, P. Airò


  • Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies

    by Clodoveo Ferri, Vincenzo Raimondo, Laura Gragnani, Dilia Giuggioli, Lorenzo Dagna, Antonio Tavoni, Francesco Ursini, Massimo L'ANdolina, Francesco Caso, Piero Ruscitti, et al.

    Objective: Autoimmune systemic diseases (ASD) represent a predisposing condition to COVID-19. Our prospective, observational multicenter telephone survey study aimed to investigate the prevalence, prognostic factors, and outcomes of COVID-19 in Italian ASD patients. Method: The study included 3,918 ASD pts (815 M, 3103 F; mean age 59±12SD years) consecutively recruited between March 2020 and May 2021 at the 36 referral centers of COVID-19 and ASD Italian Study Group. The possible development of COVID-19 was recorded by means of a telephone survey using a standardized symptom assessment questionnaire. Results: ASD patients showed a significantly higher prevalence of COVID-19 (8.37% vs. 6.49%; p< 0.0001) but a death rate statistically comparable to the Italian general population (3.65% vs. 2.95%). Among the 328 ASD patients developing COVID-19, 17% needed hospitalization, while mild-moderate manifestations were observed in 83% of cases. Moreover, 12/57 hospitalized patients died due to severe interstitial pneumonia and/or cardiovascular events; systemic sclerosis (SSc) patients showed a significantly higher COVID-19-related death rate compared to the general population (6.29% vs. 2.95%; p=0.018). Major adverse prognostic factors to develop COVID-19 were: older age, male gender, SSc, pre-existing ASD-related interstitial lung involvement, and long-term steroid treatment. Of note, patients treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) showed a significantly lower prevalence of COVID-19 compared to those without (3.58% vs. 46.99%; p=0.000), as well as the SSc patients treated with low dose aspirin (with 5.57% vs. without 27.84%; p=0.000). Conclusion: During the first three pandemic waves, ASD patients showed a death rate comparable to the general population despite the significantly higher prevalence of COVID-19. A significantly increased COVID-19- related mortality was recorded in only SSc patients’ subgroup, possibly favored by preexisting lung fibrosis. Moreover, ongoing long-term treatment with csDMARDs in ASD might usefully contribute to the generally positive outcomes of this frail patients’ population.